Revision 1 of EMA GVP Module V on risk management system was published on 25 April 2014, mainly to amend the requirements of part VI of the RMP as published already in the updated RMP templates, to introduce amendments in line with the new requirements for variation applications and to align the definitions of Missing information and Safety concern and their explanatory notes with legal requirements, as well as to amend the definition for Risk minimisation activity.
Categories
- 21 Century Cures Act
- 3D Printers
- AI
- Biological Products
- Biosamples
- Biosimilars
- Brexit
- CHCUK News & Articles
- CHCUK NIS Database
- Consultation
- Cures Act
- Cybersecurity
- Data Integrity
- Data Privacy
- Digital Health Technology
- EAP
- eConsent
- EFPIA
- EHR
- eletronic Signatures
- EMA
- EU Clinical Trials Regulation
- FDA 1572
- FDA Guidance
- FDAMA114
- GCP
- GCP Inspections
- GDPR
- Genetic Research
- GVP
- HIPAA
- HTA
- Human Tissue Research
- Immunological Products
- Informed Consent
- Market Access
- Medical Apps
- Medical Devices
- News
- NIS
- NIS Considerations Report
- Orphan Drugs
- PASS
- Patient Centricity
- Pragmatic Trials
- Professional Standards
- Promotion and Advertising
- PROs
- Publication Guidelines
- Rare Diseases
- Real Word Evidence
- Real World Evidence
- Real World Research Design
- Registry
- Regulatory Grade RWE
- Regulatory Intelligence
- Regulatory Science
- Reimbursement
- RWD
- Safety Management
- Sunshine Regulations
- Transparency
- Uncategorized
- Virtual Clinical Research
- Webinar
- White Paper
News
M | T | W | T | F | S | S |
---|---|---|---|---|---|---|
1 | ||||||
2 | 3 | 4 | 5 | 6 | 7 | 8 |
9 | 10 | 11 | 12 | 13 | 14 | 15 |
16 | 17 | 18 | 19 | 20 | 21 | 22 |
23 | 24 | 25 | 26 | 27 | 28 | 29 |
30 |